United Therapeutics
UTHR
554.73
-4.37
-0.78%
United Therapeutics
US · UTHR
#836 by market cap
Listed 1970
554.73
-4.37
-0.78%
Periodic snapshot; not a real-time feed.
· 2026-11-20 20:02
Recent news
-
Form 144 | United Therapeutics(UTHR.US) Officer Proposes to Sell 4.69 Million in Common StocksMarket Newswire · 2026/11/20
-
United Therapeutics(UTHR.US) Officer Sells US$4.69 Million in Common StockMarket Newswire · 2026/11/20
-
Rating change
United Therapeutics Is Maintained at Outperform by RBC CapitalDow Jones · 2026/11/6
-
United Therapeutics Announces First Clinical Xenotransplant In Its EXTEND Study Of UThymoKidney In Patients With ESRDBenzinga · 2026/11/20
-
Company notice
United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE ASEC · 2026/11/18
-
Rating change
Wells Fargo Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $703Market Newswire · 2026/11/6
-
Rating change
United Therapeutics Price Target Raised to $725.00/Share From $697.00 by RBC CapitalDow Jones · 2026/11/6
-
Rating change
H.C. Wainwright Initiates United Therapeutics(UTHR.US) With Buy Rating, Announces Target Price $660Market Newswire · 2026/11/9
-
Rating change
United Therapeutics Is Maintained at Buy by BTIGDow Jones · 2026/11/5
-
Company notice
United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer MAHON PAUL ASEC · 2026/11/20
-
Company notice
United Therapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144SEC · 2026/11/20
-
Rating change
Leerink Partners Maintains United Therapeutics(UTHR.US) With Buy Rating, Maintains Target Price $725Market Newswire · 2026/11/5
-
Company notice
United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE ASEC · 2026/11/20
-
Company notice
United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE ASEC · 2026/11/19
-
United Therapeutics(UTHR.US) Officer Sells US$5.51 Million in Common StockMarket Newswire · 2026/11/19
-
Rating change
A Quick Look at Today's Ratings for United Therapeutics(UTHR.US), With a Forecast Between $650 to $768Market Newswire · 2026/11/5
-
United Therapeutics(UTHR.US) Officer Sells US$3.13 Million in Common StockMarket Newswire · 2026/11/20
-
Rating change
United Therapeutics Is Maintained at Overweight by Wells FargoDow Jones · 2026/11/5
-
Rating change
TD Cowen Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $700Market Newswire · 2026/11/5
-
Rating change
RBC Capital Maintains United Therapeutics(UTHR.US) With Buy Rating, Raises Target Price to $725Market Newswire · 2026/11/5
-
United Therapeutics(UTHR.US) Officer Sells US$5.5 Million in Common StockMarket Newswire · 2026/11/7
-
Company notice
United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE ASEC · 2026/11/7
-
Company notice
United Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer ROTHBLATT MARTINE ASEC · 2026/11/6
-
Rating change
United Therapeutics Price Target Cut to $695.00/Share From $710.00 by JP MorganDow Jones · 2026/10/29
-
United Therapeutics Insider Sold Shares Worth $1,171,609, According to a Recent SEC FilingMT Newswires · 2026/11/7
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 20:02:22 · For reference only, not investment advice and not tailored to your situation.
United Therapeutics discussion 0 comments